Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Mar 23, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

3.0K

Molecular techniques for predicting behaviour in melanocytic neoplasms.

Christina Y Lee1, Pedram Gerami1

  • 1Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Pathology
|March 30, 2016
PubMed
Summary

Molecular assays offer new ways to diagnose, predict, and treat melanocytic neoplasms. These tools improve melanoma patient care by distinguishing aggressive from indolent tumors, guiding therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical, morphological, and genomic features of FGFR fusion Spitz neoplasms.

Pathology·2026
Same author

ERBB fusions in Spitz neoplasms, expanding the spectrum of Spitz-associated genomic fusions.

Pathology·2026
Same author

Clinical Outcomes and Prognostication of CRTC1::TRIM11 Fusion Cutaneous Tumors.

The American journal of surgical pathology·2026
Same author

Use of ancillary studies in pediatric spitzoid neoplasms: A retrospective cohort study.

Journal of the American Academy of Dermatology·2026
Same author

Sclerodermoid cutaneous metastases secondary to prostate adenocarcinoma.

JAAD case reports·2026
Same author

Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6.

Clinical lymphoma, myeloma & leukemia·2026

Area of Science:

  • Oncology
  • Dermatology
  • Molecular Diagnostics

Background:

  • Molecular tools are becoming essential for cancer patient care.
  • In melanocytic neoplasms, these assays aid in diagnosis, prognosis, and theranosis.
  • Developing therapeutic options for melanoma necessitate improved patient stratification.

Purpose of the Study:

  • To review traditional melanoma staging.
  • To identify opportunities for molecular strategies in melanoma assessment.
  • To discuss available molecular assays for melanocytic neoplasms.

Main Methods:

  • Review of current literature on molecular assays.
  • Evaluation of techniques including fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), mRNA expression profiling, and next-generation sequencing (NGS).
Keywords:
Melanomacomparative genomic hybridisationfluorescence in situ hybridisationmRNA expression profilingmolecular therapynext generation sequencing

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.8K
A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

13.3K

Related Experiment Videos

Last Updated: Mar 23, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

3.0K
A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.8K
A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

13.3K

Main Results:

  • Molecular assays offer improved diagnostic accuracy for ambiguous tumors.
  • Prognostic capabilities enhance patient stratification for conventional melanoma.
  • Theranostic applications are emerging for advanced melanoma cases.

Conclusions:

  • Molecular strategies represent a significant advancement in managing melanocytic neoplasms.
  • Optimizing the utilization of various molecular assays is crucial for clinical practice.
  • These tools are vital for personalizing melanoma treatment and improving patient outcomes.